Siminder Atwal

1.2k total citations
15 papers, 907 citations indexed

About

Siminder Atwal is a scholar working on Genetics, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Siminder Atwal has authored 15 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 7 papers in Oncology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Siminder Atwal's work include Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Siminder Atwal is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Siminder Atwal collaborates with scholars based in United States, Australia and New Zealand. Siminder Atwal's co-authors include Elizabeth A. Punnoose, Mark R. Lackner, Andrea Pirzkall, Lukas C. Amler, Bernard M. Fine, Weiqun Liu, Brett Hughes, Rajiv Raja, Rodney J. Hicks and Garret M. Hampton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Siminder Atwal

14 papers receiving 890 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Siminder Atwal United States 11 607 384 250 222 198 15 907
Alex Pearson United Kingdom 9 918 1.5× 537 1.4× 823 3.3× 91 0.4× 219 1.1× 16 1.5k
Thomas A. Summers United States 12 321 0.5× 150 0.4× 75 0.3× 186 0.8× 89 0.4× 32 566
NE Davidson United States 6 542 0.9× 275 0.7× 96 0.4× 48 0.2× 69 0.3× 15 787
Christopher D. Carey United States 12 593 1.0× 191 0.5× 93 0.4× 330 1.5× 158 0.8× 16 1.3k
Mikel Lipschitz United States 10 786 1.3× 125 0.3× 168 0.7× 330 1.5× 64 0.3× 14 1.0k
Samuel Berman United States 10 424 0.7× 162 0.4× 69 0.3× 84 0.4× 39 0.2× 21 780
Bernhard Polzer Germany 16 791 1.3× 620 1.6× 237 0.9× 83 0.4× 22 0.1× 34 1.2k
Eman L. Dadashian United States 7 304 0.5× 126 0.3× 76 0.3× 111 0.5× 135 0.7× 8 536
BW Cooper United States 5 500 0.8× 253 0.7× 87 0.3× 58 0.3× 78 0.4× 9 763
Heather Homer United States 4 552 0.9× 171 0.4× 82 0.3× 440 2.0× 192 1.0× 4 837

Countries citing papers authored by Siminder Atwal

Since Specialization
Citations

This map shows the geographic impact of Siminder Atwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Siminder Atwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Siminder Atwal more than expected).

Fields of papers citing papers by Siminder Atwal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Siminder Atwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Siminder Atwal. The network helps show where Siminder Atwal may publish in the future.

Co-authorship network of co-authors of Siminder Atwal

This figure shows the co-authorship network connecting the top 25 collaborators of Siminder Atwal. A scholar is included among the top collaborators of Siminder Atwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Siminder Atwal. Siminder Atwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Cheson, Bruce D., Franck Morschhauser, Sarit Assouline, et al.. (2023). A PHASE 1 STUDY EVALUATING PRT2527, A POTENT AND HIGHLY SELECTIVE CDK9 INHIBITOR, IN PATIENTS WITH SELECT RELAPSED/REFRACTORY B‐CELL MALIGNANCIES. Hematological Oncology. 41(S2). 829–830. 1 indexed citations
2.
Tam, Constantine S., Stephen Opat, David Simpson, et al.. (2021). Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Advances. 5(12). 2577–2585. 63 indexed citations
3.
Bachanová, Veronika, Armin Ghobadi, Krish Patel, et al.. (2021). Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma. Blood. 138(Supplement 1). 823–823. 65 indexed citations
4.
Patel, Krish, Veronika Bachanová, Aaron M. Goodman, et al.. (2021). Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma. Blood. 138(Supplement 1). 3873–3873. 14 indexed citations
5.
6.
Trotman, Judith, Stephen Opat, David Gottlieb, et al.. (2020). Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 136(18). 2027–2037. 73 indexed citations
7.
Tam, Constantine S., Stephen Opat, Paula Marlton, et al.. (2020). Three-year follow-up of treatment-naïve and previously treated patients with Waldenström macroglobulinemia (WM) receiving single-agent zanubrutinib.. Journal of Clinical Oncology. 38(15_suppl). 8051–8051. 4 indexed citations
8.
9.
10.
Tam, Constantine S., M. Wang, David Simpson, et al.. (2019). UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111). Hematological Oncology. 37(S2). 245–247. 24 indexed citations
11.
Tam, Constantine S., Véronique Leblond, William Novotny, et al.. (2018). A Head-To-Head Phase III Study Comparing Zanubrutinib Versus Ibrutinib in Patients with Waldenström Macroglobulinemia. Future Oncology. 14(22). 2229–2237. 27 indexed citations
12.
Punnoose, Elizabeth A., Siminder Atwal, Weiqun Liu, et al.. (2012). Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib. Clinical Cancer Research. 18(8). 2391–2401. 341 indexed citations
13.
Savage, Heidi, et al.. (2012). Abstract 966: Predictive biomarkers of the AKT inhibitor, GDC-0068, in single agent and combination studies. Cancer Research. 72(8_Supplement). 966–966. 2 indexed citations
14.
Punnoose, Elizabeth A., Siminder Atwal, Jill M. Spoerke, et al.. (2010). Molecular Biomarker Analyses Using Circulating Tumor Cells. PLoS ONE. 5(9). e12517–e12517. 238 indexed citations
15.
Atwal, Siminder, Daniel Chen, Mark R. Lackner, & Elizabeth A. Punnoose. (2010). Molecular biomarker analyses using circulating tumor cells. Clinical Cancer Research. 16(19_Supplement). PR3–PR3. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alex Pearson Breakdown of academic impact, for papers by Thomas A. Summers Breakdown of academic impact, for papers by NE Davidson Breakdown of academic impact, for papers by Christopher D. Carey Breakdown of academic impact, for papers by Mikel Lipschitz Breakdown of academic impact, for papers by Samuel Berman Breakdown of academic impact, for papers by Bernhard Polzer Breakdown of academic impact, for papers by Eman L. Dadashian Breakdown of academic impact, for papers by BW Cooper Breakdown of academic impact, for papers by Heather Homer
Rankless by CCL
2026